{"id":"W2573399798","doi":"10.1182/blood.v126.23.4228.4228","title":"Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; University of Alberta","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Tolerability; Internal medicine; Clinical endpoint; Progressive disease; Dexamethasone; Refractory (planetary science); Neutropenia; Gastroenterology; Phases of clinical research; Population; Urology; Bortezomib; Multiple myeloma; Pharmacology; Oncology; Clinical trial; Adverse effect; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008738509,0.0005151962,0.0007988026,0.0002845397,0.0001514739,0.0006796625,0.0004820737,0.0005190072,0.004343433],"category_scores_gemma":[0.0003074794,0.0001945883,0.0007926158,0.0002818365,0.0003141024,0.0003303561,0.0002437018,0.001606529,0.0009207429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009151912,"about_ca_system_score_gemma":0.0008100681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008889849,"about_ca_topic_score_gemma":0.003726324,"domain_scores_codex":[0.9997968,0.00007915577,0.00001158749,0.000037597,0.00003467207,0.00004026666],"domain_scores_gemma":[0.9997554,0.00003259263,0.00005622771,0.00002213102,0.00001669766,0.0001168978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2734798,0.02146308,0.02224896,0.001884469,0.002580504,0.0007053172,0.0002151471,0.00361028,0.1293683,0.001358876,0.0315764,0.5115089],"study_design_scores_gemma":[0.4513682,0.2998669,0.08737499,0.0003062137,0.00251367,0.003467747,0.0001238024,0.004808658,0.07165331,0.0007389229,0.07768694,0.00009066529],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9600978,0.01510909,0.0007917815,0.001050466,0.0001722093,0.001175222,0.002860854,0.000256994,0.01848545],"genre_scores_gemma":[0.9834471,0.004265998,0.001156073,0.0008527195,0.0001273471,0.0002852512,0.00457783,0.00003185886,0.005255763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004343433,"threshold_uncertainty_score":0.01453018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01544769349969395,"score_gpt":0.2545100883772734,"score_spread":0.2390623948775795,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}